In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbα

In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbα

Abstract The interaction of platelet GPIbα with von Willebrand factor (VWF) is essential to initiate platelet adhesion and thrombosis, particularly under high shear stress conditions. However, no drug targeting GPIbα has been developed for clinical practice. Here we characterized anfibatide, a GPIbα...

Full description

Bibliographic Details
Main Authors: Benjamin Xiaoyi Li, Xiangrong Dai, Xiaohong Ruby Xu, Reheman Adili, Miguel Antonio Dias Neves, Xi Lei, Chuanbin Shen, Guangheng Zhu, Yiming Wang, Hui Zhou, Yan Hou, Tiffany Ni, Yfke Pasman, Zhongqiang Yang, Fang Qian, Yanan Zhao, Yongxiang Gao, Jing Liu, Maikun Teng, Alexandra H. Marshall, Eric G. Cerenzia, Mandy Lokyee Li, Heyu Ni
Format: Article
Language:English
Published: Nature Publishing Group 2021-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-91165-8

Internet

https://doi.org/10.1038/s41598-021-91165-8

Similar Items